Key Events This Week
18 May: Stock opens at Rs.2,496.35, declines 0.30% amid broader market weakness
20 May: Strong quarterly results announced; stock surges 3.58% with record volumes and derivatives activity
21 May: Quality grade upgraded to Excellent, boosting investor confidence
22 May: Mojo Grade downgraded to Hold, triggering profit-taking and a 1.37% drop
Weekly Close: Rs.2,480.50, down 0.93% vs Sensex +0.50%
18 May 2026: Modest Decline Amid Market Weakness
Mankind Pharma began the week at Rs.2,496.35, slipping 0.30% on relatively subdued volume of 78,572 shares. The broader market was also weak, with the Sensex falling 0.35% to 35,114.86. This initial decline reflected cautious investor sentiment ahead of the company’s quarterly results announcement. The stock’s performance was broadly in line with the market, showing no significant divergence at this stage.
19 May 2026: Slight Dip Despite Sensex Gains
The stock edged down further by 0.09% to Rs.2,494.10 on lighter volume of 40,869 shares, even as the Sensex rebounded 0.25% to 35,201.48. This divergence suggested some profit-booking or consolidation ahead of the earnings release. Delivery volumes declined by 21.47% compared to the five-day average, indicating reduced long-term investor participation despite the market’s positive tone.
20 May 2026: Strong Quarterly Results Spark Rally and Heavy Trading
Mankind Pharma’s quarterly results for Q4 FY26, released on 20 May, marked a pivotal moment for the stock. The company reported record-high profitability with PBDIT at ₹929.88 crores and PAT of ₹574.01 crores, translating into an EPS of ₹13.43. Operating margins expanded to 27.01%, and the financial trend was upgraded from flat to positive, signalling robust operational efficiency.
In response, the stock surged 3.58% to close at Rs.2,583.35, its weekly high, on a massive volume of 265,490 shares. It outperformed the Sensex, which gained a modest 0.28%. The day also saw exceptional derivatives activity, with call option volumes surging at the 2,560 and 2,600 strike prices, and a 14.9% increase in open interest, reflecting bullish market positioning. Put option volumes also rose, indicating some hedging amid optimism.
Despite the rally, delivery volumes remained subdued, suggesting that short-term traders dominated the session. The stock’s technical indicators were positive, trading above all key moving averages, reinforcing the bullish momentum.
This week's revealed pick, a Large Cap from Public Banks with TARGET PRICE, is already showing movement! Get the complete analysis before it's too late.
- - Target price included
- - Early movement detected
- - Complete analysis ready
21 May 2026: Quality Grade Upgrade Boosts Confidence
On 21 May, Mankind Pharma was upgraded to an Excellent Quality Grade, reflecting strong business fundamentals including superior return ratios, prudent debt management, and consistent growth. This upgrade followed the robust quarterly performance and was accompanied by a Mojo Score increase to 72.0 and a Buy rating. The stock closed at Rs.2,514.95, down 2.65% from the previous day’s high, as some profit-taking emerged after the sharp rally.
The downgrade in Mojo Grade from Sell to Hold had occurred earlier on 8 May, but the quality upgrade on 21 May was a positive signal for investors. Despite the slight price dip, the company’s fundamentals were viewed favourably relative to peers, with strong ROCE of 21.63% and ROE of 16.64%, and low leverage ratios.
22 May 2026: Mojo Grade Downgrade Triggers Profit-Taking
On 22 May, MarketsMOJO downgraded Mankind Pharma’s Mojo Grade from Buy to Hold, citing mixed financial and valuation signals despite strong quarterly results. Concerns included a relatively low cash position of ₹482.77 crores and a premium valuation with a PEG ratio of 33.8. The quality grade was also downgraded from Excellent to Good, reflecting a more cautious outlook.
This reassessment led to a 1.37% decline in the stock price to Rs.2,480.50 on low volume of 29,513 shares. The Sensex continued its upward trend, gaining 0.21%, highlighting the stock’s underperformance. The downgrade tempered investor enthusiasm and prompted some profit-taking after the week’s earlier gains.
| Date | Stock Price | Day Change | Sensex | Day Change |
|---|---|---|---|---|
| 2026-05-18 | Rs.2,496.35 | -0.30% | 35,114.86 | -0.35% |
| 2026-05-19 | Rs.2,494.10 | -0.09% | 35,201.48 | +0.25% |
| 2026-05-20 | Rs.2,583.35 | +3.58% | 35,299.20 | +0.28% |
| 2026-05-21 | Rs.2,514.95 | -2.65% | 35,340.31 | +0.12% |
| 2026-05-22 | Rs.2,480.50 | -1.37% | 35,413.94 | +0.21% |
Key Takeaways
Positive Signals: The company’s record quarterly earnings and margin expansion demonstrated operational strength amid sector challenges. The upgrade to Excellent Quality Grade and strong return ratios highlight robust fundamentals. The surge in derivatives activity and open interest on 20 May reflected bullish market sentiment and renewed investor interest.
Cautionary Signals: Despite strong earnings, the stock ended the week lower, underperforming the Sensex by 1.43%. The downgrade in Mojo Grade to Hold and quality grade to Good on 22 May raised concerns over valuation premium and liquidity. Declining delivery volumes suggest reduced long-term investor participation, signalling potential volatility ahead.
Market Context: Mankind Pharma’s mid-cap status and sector positioning provide growth opportunities but also expose it to regulatory and pricing risks. The mixed signals from fundamental upgrades and rating downgrades warrant close monitoring of price action and volume trends in the near term.
Holding Mankind Pharma Ltd from ? See if there's a smarter choice! SwitchER compares it with peers and suggests superior options across market caps and sectors!
- - Peer comparison ready
- - Superior options identified
- - Cross market-cap analysis
Conclusion
Mankind Pharma Ltd’s week was marked by a strong midweek rally fuelled by record quarterly profits and a quality grade upgrade, followed by a late-week correction triggered by a Mojo Grade downgrade and valuation concerns. The stock’s underperformance relative to the Sensex despite positive fundamentals highlights the complex interplay of growth prospects and market caution. Investors should weigh the company’s operational strength and improving financial trends against premium valuation and mixed market signals. Monitoring delivery volumes, derivatives activity, and rating changes will be crucial to understanding the stock’s near-term trajectory in a dynamic pharmaceutical sector environment.
Only Rs. 20,999 - Get MojoOne + Stock of the Week for 3 Years Get 71% Off →
